Analysis of the efficacy and influence factors for treatment of primary hepatocellular carcinoma by Huachansu tablets combined with transarterial chemoembolization

Abstract

Objective To evaluate the efficacy of Huachansu tablets combined with transarterial chemoembolization (TACE) for treatment of primary hepatocellular carcinoma (HCC) and prognostic influence factors. Methods One hundred and eight patients with HCC were recruited according to the inclusion and exclusion criteria. Patients were randomly divided into treatment group and control group. The treatment group was treated with Huachansu tablets combined with TACE, and the control group was treated with TACE alone, with overall survival time (OS) and progression-free survival time (PFS) as the evaluation indexes. The COX regression analysis was used to evaluate the survival and prognostic effects and their influence factors in both groups. Results A total of 108 HCC patients were enrolled. The OS was 13.5 months in treatment group and 9.2 months in control group; the PFS was 6.8 months in treatment group and 5.3 months in control group, and the differences were significant statistically (all P<0.05). Multivariate COX regression analysis showed that Child-Pugh grade and cirrhosis were the independent risk factors for PFS in HCC patients. Child-Pugh grade were the independent risk factors for OS in HCC patients. ALBI is a protective factor for OS in HCC patients. Conclusions The treatment of HCC by Huachansu tablets combined with TACE can delay the progression of HCC and prolong PFS and OS of the patients with HCC. Child-Pugh grade, cirrhosis status, and ALBI were important factors affecting the prognosis of the patients with HCC.

Keywords

• |hepatocellular carcinoma(hcc)|huachansu tablet|transarterial chemoembolization(tace)|influencing factor